Document is current
Any future updates will be listed below
-
Authors
Brawley, Douglas N.
Sauer, David B.
Li, Jianping
Zheng, Xuhui
Koide, Akiko
Jedhe, Ganesh S. https://orcid.org/0000-0001-7404-3677
Suwatthee, Tiffany
Song, Jinmei
Liu, Zheng https://orcid.org/0000-0002-3538-9349
Arora, Paramjit S.
Koide, Shohei https://orcid.org/0000-0001-5473-4358
Torres, Victor J. https://orcid.org/0000-0002-7126-0489
Wang, Da-Neng https://orcid.org/0000-0002-6496-4699
Traaseth, Nathaniel J. https://orcid.org/0000-0002-1185-6088
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM088118, R35GM130333, R01GM121994)
American Cancer Society (129844-PF-17-135-01-TBE)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI099394, R01AI105129, R01AI137336, R01AI140754, R21AI149350, R01AI108889, R01AI165782)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS108151)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK099023)
NSF | BIO | Division of Molecular and Cellular Biosciences (1902449)
- License Information
-
More Information
Article History
Received: 21 July 2021
Accepted: 8 February 2022
First Online: 31 March 2022
Competing interests
: S.K. is a SAB member and holds equity in and receives consulting fees from Black Diamond Therapeutics, a co-founder of and holds equity in Revalia Bio, and receives research funding from Puretech Health and Argenx BVBA. V.J.T. is an inventor on patents and patent applications filed by NYU, which are currently under commercial license to Janssen Biotech Inc. Janssen Biotech Inc. provides research funding and other payments associated with the licensing agreement. All other authors declare no competing interests. NYU has filed a provisional patent application covering the NorA inhibitors described in this work.
